Read Summary

Novartis said on Thursday it had temporarily suspended the production of its Lutathera and Pluvicto cancer therapies at facilities in Italy and New Jersey after potential quality issues were discovered in their manufacturing.
Reuters Health Information

Print Friendly, PDF & Email